Gísli: Not sure how this bad news passed us by from the end of 2024! Maybe we were preoccupied by other things?! 😱 www.fiercebiotech.com/biotech/amge...

See full post

Gísli ipfdoc.bsky.social
Not sure how this bad news passed us by from the end of 2024! Maybe we were preoccupied by other things?! 😱 www.fiercebiotech.com/biotech/amge...
Amgen ghosts lung disease program after missing all 14 endpoints

Amgen is discontinuing a lung disease program after its investigation | Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any of the primary or secon...

fiercebiotech.com
Feb 18, 2025 17:59
0 reposts 0 quotes 0 likes

View on Bluesky Show all post labels
Michael Gilman gilman.bsky.social · Feb 18
Missed all 14 endpoints - impressive!

View on Bluesky Show all post labels
Gísli ipfdoc.bsky.social · Feb 18
I know! Resoundingly negative!

View on Bluesky Show all post labels
Michael Gilman gilman.bsky.social · Feb 18
A good experiment. Conclusive.

View on Bluesky Show all post labels
Gísli ipfdoc.bsky.social · Feb 18
So the next question is a drug effect or a target effect. I guess time will tell.

View on Bluesky Show all post labels
Michael Gilman gilman.bsky.social · Feb 18
Never a fan of that target. But haven't followed for approximately a decade.

View on Bluesky Show all post labels
Gísli ipfdoc.bsky.social · Feb 18
It’s a popular pathway to target, but I tend to agree with you.

View on Bluesky Show all post labels

An unhandled error has occurred. Reload 🗙